Dear Mr. Cammarata:

Please refer to your Supplemental New Drug Application (sNDA) dated and received April 10, 2017, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Children’s Flonase Allergy Relief (fluticasone propionate nasal spray) 50 mcg per metered spray.

This “Prior Approval” supplemental new drug application provides for revision of the statement of identity as part of the glucocorticoid class labeling and changes to the net weight statement.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

We have approved package sizes for this product amid concerns that consumers follow instructions that limit duration of use of over-the-counter nasal corticosteroids to no longer than 2 months a year in children. The “Directions” section of the drug facts labeling for the product states “Talk to your child’s doctor if your child needs to use the spray for longer than two months a year.”

Research has shown that increased package sizing of products leads to increased usage among consumers. 1,2 Conversely, limiting pack sizes of medication has been shown to reduce episodes of overconsumption by limiting the immediate availability of the drug to the consumer. 3,4

If you are interested in marketing a package configuration that would extend use beyond 2 months, we advise you to request a meeting with us to discuss the safety and efficacy implications, consumer use patterns, and data needed to support a prior approval supplement submission.

**LABELING**

Submit final printed labeling as soon as they are available, but no more than 30 days after they are printed. The final printed labeling (FPL) must be identical to the enclosed labeling described in the table below and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

<table>
<thead>
<tr>
<th>Submitted Labeling</th>
<th>Submission Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 x 60-spray count blister card front</td>
<td>5/4/17</td>
</tr>
<tr>
<td>2 x 60-spray count blister card back</td>
<td>5/4/17</td>
</tr>
<tr>
<td>60-spray count blister card</td>
<td>5/4/17</td>
</tr>
<tr>
<td>60-spray count bottle label</td>
<td>8/16/17</td>
</tr>
</tbody>
</table>

The final printed labeling should be submitted electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3).* For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 205434 S-005.**” Approval of this submission by FDA is not required before the labeling is used.

**DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm).

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf). In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.
**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sherry Stewart, Regulatory Project Manager, at (301) 796-9618.

Sincerely,

*See appended electronic signature page*

Theresa Michele, MD
Director
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

**ENCLOSURES:**
Carton and Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THERESA M MICHELE
08/31/2017